Novel Effects of Macrolide Antibiotics on Cardiovascular Diseases

Cardiovascular Therapeutics

Volumn 30, Issue 6, 2012, Pages 301-307

  Suzuki, Jun Ichi ^a   Ogawa, Masahito ^a   Hishikari, Keiichi ^b   Watanabe, Ryo ^b   Takayama, Kiyoshi ^c   Hirata, Yasunobu ^a   Nagai, Ryozo ^a   Isobe, Mitsuaki ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c NB Health Laboratory   (Japan)

Author keywords

Inflammation; Macrolide; Matrix metalloproteinases; Myocardial remodeling

Indexed keywords

CLARITHROMYCIN; COLLAGENASE 3; CYCLOSPORIN; DOXYCYCLINE; ERYTHROMYCIN; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; JOSAMYCIN; MACROLIDE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; ROXITHROMYCIN; TACROLIMUS; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSCRIPTION FACTOR RUNX2;

ACUTE GRAFT REJECTION; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; BRONCHIOLITIS; CARDIAC GRAFT REJECTION; CARDIOVASCULAR DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GRAFT SURVIVAL; HEART FAILURE; HEART INFARCTION; HEART INFARCTION PREVENTION; HUMAN; INFECTION; INFLAMMATORY INFILTRATE; MACROPHAGE; MUSCULOSKELETAL DISEASE; MYOCARDITIS; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIODONTAL DISEASE; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; UNSPECIFIED SIDE EFFECT; UPREGULATION;

ANIMALS; ANTI-BACTERIAL AGENTS; CARDIOVASCULAR DISEASES; HEART TRANSPLANTATION; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MACROLIDES; MATRIX METALLOPROTEINASES; MYOCARDIAL ISCHEMIA; MYOCARDITIS; REGENERATION;

EID: 84869084761     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2011.00303.x     Document Type: Review

References (90)

1. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011;473:317-325.
2. Kebschull M, Demmer RT, Papapanou PN. "Gum bug, leave my heart alone!"- Epidemiologic and mechanistic evidence linking periodontal infections and atherosclerosis. J Dent Res 2010;89:879-902.
3. Vainas T, Sayed S, Bruggeman CA, Stassen FR. Exploring the role of Chlamydia pneumoniae in cardiovascular disease: A narrative review. Drugs Today 2009;45(Suppl B):165-172.
4. Muhlestein JB. Antibiotic treatment of atherosclerosis. Curr Opin Lipidol 2003;14:605-614.
5. Sinisalo J, Mattila K, Valtonen V, et al. Clarithromycin in Acute Coronary Syndrome Patients in Finland (CLARIFY) Study Group. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. Circulation 2002;105:1555-1560.
6. Paju S, Pussinen PJ, Sinisalo J, et al. Clarithromycin reduces recurrent cardiovascular events in subjects without periodontitis. Atherosclerosis 2006;188:412-419.
7. Paakkanen R, Palikhe A, Seppänen M, et al. Beneficial effect of clarithromycin in patients with acute coronary syndrome and complement C4 deficiencies. Scand Cardiovasc J 2009;43:395-401.
8. Jespersen CM, Als-Nielsen B, Damgaard M, et al. CLARICOR Trial Group: Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ 2006;332:22-27.
9. Jensen GB, Hilden J, Als-Nielsen B, et al. CLARICOR Trial Group: Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. J Cardiovasc Pharmacol 2010;55:123-128.
10. Berg HF, Maraha B, Scheffer GJ, Peeters MF, Kluytmans JA. Effect of clarithromycin on inflammatory markers in patients with atherosclerosis. Clin Diagn Lab Immunol 2003;10:525-528.
11. Marjanović N, Bosnar M, Michielin F, et al. Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro. Pharmacol Res 2011;63:389-397.
12. Kikuchi T, Hagiwara K, Honda Y, et al. Clarithromycin suppresses lipopolysaccharide- induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors. J Antimicrob Chemother 2002;49:745-755.
13. Abe S, Nakamura H, Inoue S, et al. Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. Am J Respir Cell Mol Biol 2000;22:51-60.
14. Cooper LT Jr. Myocarditis. N Engl J Med 2009;360:1526-1538.
15. Kawai C. From Myocarditis to cardiomyopathy: Mechanism of inflammation and cell death. Learning from the past for the future. Circulation 1999;99:1091-1100.
16. Kodama M, Hanawa H, Saeki M, Hosono H, Inomata T, Suzuki K, Shibata A. Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ Res 1994;75:278-284.
17. Heymans S, Pauschinger M, De Palma A, et al. Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis. Circulation 2006; 114:565-573.
18. Suzuki J, Isobe M, Kawauchi M, Endoh M, Amano J, Takamoto S. Altered expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in acutely rejected myocardium and coronary arteriosclerosis in cardiac allografts of nonhuman primates. Transplant Int 2000;13:106-113.
19. Yamani MH, Starling RC, Young JB, et al. Acute vascular rejection is associated with up- regulation of vitronectin receptor (alphavbeta3), increased expression of tissue factor, and activation of the extracellular matrix metalloproteinase induction system. J Heart Lung Transplant 2002;21:983-989.
20. Lalu MM, Pasini E, Schulze CJ, Ferrari-Vivaldi M, Ferrari-Vivaldi G, Bachetti T, Schulz R. Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart. Eur Heart J 2005;26:27-35.
21. Deschamps AM, Yarbrough WM, Squires CE, et al. Trafficking of the membrane type-1 matrix metalloproteinase in ischemia and reperfusion: Relation to interstitial membrane type-1 matrix metalloproteinase activity. Circulation 2005;111:1166-1174.
22. Freestone T, Turner RJ, Coady A, Higman DJ, Greenhalgh RM, Powell JT. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 1995;15:1145-1151.
23. Davis V, Persidskaia R, Baca-Regen L, et al. Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 1998;18:1625-1633.
24. Clutterbuck AL, Asplin KE, Harris P, Allaway D, Mobasheri A. Targeting matrix metalloproteinases in inflammatory conditions. Curr Drug Targets 2009;10:1245-54.
25. Xia M, Leppert D, Hauser SL, Sreedharan SP, Nelson PJ, Krensky AM, Goetzl EG. Stimulus specificity of matrix metalloproteinase dependence of human T cell migration through a model basement membrane. J Immunol 1996;156:160-167.
26. Hashimoto N, Kawabe T, Hara T, et al. Effect of erythromycin on matrix metalloproteinase-9 and cell migration. J Lab Clin Med 2001;137:176-183.
27. Li J, Schwimmbeck PL, Tschope C, et al. Collagen degradation in a murine myocarditis model: Relevance of matrix metalloproteinase in association with inflammatory induction. Cardiovasc Res 2002;56:235-247.
28. Mazzarella G, Petillo O, Margarucci S, Calabrese C, Peluso G. Role of monocyte/macrophage population in immune response. Monaldi Arch Chest Dis 1998;53:92-96.
29. Cho A, Reidy MA. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ Res 2002;91:845-851.
30. Tang Q, Huang J, Qian H, et al. Microarray analysis reveals the role of matrix metalloproteinases in mouse experimental autoimmune myocarditis induced by cardiac myosin peptides. Cell Mol Biol Lett 2007;12:176-191.
31. Ermolli M, Schumacher M, Lods N, Hammoud M, Marti HP. Differential expression of MMP-2/MMP-9 and potential benefit of an MMP inhibitor in experimental acute kidney allograft rejection. Transpl Immunol 2003;11:137-145.
32. Ascher NL, Ferguson RM, Hoffman R, Simmons RL. Partial characterization of cytotoxic cells infiltrating sponge matrix allografts. Transplantation 1979;27:254-259.
33. Isobe M, Suzuki J. New approaches to the management of acute and chronic cardiac allograft rejection. Jpn Circ J 1998;62:315-327.
34. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357:1121-1135.
35. Dirksen MT, Laarman GJ, Simoons ML, Duncker DJ. Reperfusion injury in humans: A review of clinical trials on reperfusion injury inhibitory strategies. Cardiovasc Res 2007;74:343-355.
36. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002;53:31-47.
37. Hakuno D, Kimura N, Yoshioka M, et al. Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in humans and rodents. J Clin Invest 2010;120:2292-306.
38. Hansson J, Lind L, Hulthe J, Sundström J. Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: A population-based study. Eur J Cardiovasc Prev Rehabil 2009;16:297-303.
39. Wei L. Immunological aspect of cardiac remodeling: T lymphocyte subsets in inflammation-mediated cardiac fibrosis. Exp Mol Pathol 2011;90:74-78.
40. Dormán G, Cseh S, Hajdú I, et al. Matrix metalloproteinase inhibitors: A critical appraisal of design principles and proposed therapeutic utility. Drugs 2010;70:949-964.
41. Dormán G, Kocsis-Szommer K, Spadoni C, Ferdinandy P. MMP inhibitors in cardiac diseases: An update. Recent Pat Cardiovasc Drug Discov 2007;2:186-194.
42. Chow AK, Cena J, Schulz R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol 2007;152:189-205.
43. Moshal KS, Rodriguez WE, Sen U, Tyagi SC. Targeted deletion of MMP-9 attenuates myocardial contractile dysfunction in heart failure. Physiol Res 2008;57:379-384.
44. Campbell LG, Ramachandran S, Liu W, et al. Different roles for matrix metalloproteinase-2 and matrix metalloproteinase-9 in the pathogenesis of cardiac allograft rejection. Am J Transplant 2005;5:517-528.
45. Cheung C, Marchant D, Walker EK, et al. Ablation of matrix metalloproteinase-9 increases severity of viral myocarditis in mice. Circulation 2008;117:1574-1582.
46. Corbitt CA, Lin J, Lindsey ML. Mechanisms to inhibit matrix metalloproteinase activity: Where are we in the development of clinically relevant inhibitors?Recent Pat Anticancer Drug Discov 2007;2:135-142.
47. Caton J, Ryan ME. Clinical studies on the management of periodontal diseases utilizing subantimicrobial dose doxycycline (SDD). Pharmacol Res 2011;63:114-120.
48. Shinkai M, Foster GH, Rubin BK. Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 2006;290:L75-L85.
49. Suzuki T, Yamaya M, Sekizawa K, et al. Erythromycin inhibits rhinovirus infection in cultured human tracheal epithelial cells. Am J Respir Crit Care Med 2002;165:1113-1118.
50. Oda H, Kadota J, Kohno S, Hara K. Leukotriene B4 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Chest 1995;108:116-122.
51. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with lowdose erythromycin. Am J Respir Crit Care Med 1998;157:1829-1832.
52. Nakanishi Y, Kobayashi D, Asano Y, et al. Clarithromycin prevents smoke-induced emphysema in mice. Am J Respir Crit Care Med 2009;179:271-278.
53. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008;177:148-55.
54. Kanai K, Asano K, Hisamitsu T, Suzaki H. Suppression of matrix metalloproteinase-9 production from neutrophils by a macrolide antibiotic, roxithromycin, in vitro. Mediators Inflamm 2004;13:313-319.
55. Kanai K, Asano K, Hisamitsu T, Suzaki H. Suppression of matrix metalloproteinase production from nasal fibroblasts by macrolide antibiotics in vitro. Eur Respir J 2004;23:671-678.
56. Abdul-Hussien H, Hanemaaijer R, Verheijen JH, van Bockel JH, Geelkerken RH, Lindeman JH. Doxycycline therapy for abdominal aneurysm: Improved proteolytic balance through reduced neutrophil content. J Vasc Surg 2009;49:741-9.
57. Guo H, Lee JD, Yue H, et al. Effect of erythromycin on homocysteine-induced extracellular matrix metalloproteinase-2 production in cultured rat vascular smooth muscle cells. Indian J Med Res 2005;121:764-770.
58. Tabuchi S, Sakuta T, Oyama T, et al. Runt-related gene 2 is involved in the inhibition of matrix metalloproteinase-13 expression by roxithromycin in human gingival epithelial cell cultures. J Periodontal Res 2009;44:283-288.
59. Yokoseki O, Suzuki J, Kitabayashi H, et al. cis element decoy against neculear factor-kB attenuates development of experimental autoimmune myocarditis in rats. Circ Res 2001;89:899-906.
60. Futamatsu H, Suzuki J, Kosuge H, et al. Attenuation of experimental autoimmune myocarditis by blocking activated T cells through inducible costimulatory molecule pathway. Cardiovasc Res 2003;59:95-104.
61. Suzuki J, Ogawa M, Futamatsu H, Kosuge H, Tanaka H, Isobe M. A cyclooxygenase-2 inhibitor alters Th1/Th2 cytokine balance and suppresses autoimmune myocarditis in rats. J Mol Cell Cardiol 2006;40:688-695.
62. Suzuki J, Ogawa M, Futamatsu H, Kosuge H, Sagesaka YM, Isobe M. Tea catechins improve left ventricular dysfunction, suppress myocardial inflammation, fibrosis, and alter cytokine expression in rat autoimmune myocarditis. Eur J Heart Fail 2007;9:152-159.
63. Maeda K, Shioi T, Kosugi R, Yoshida Y, Takahashi K, Machida Y, Izumi T. Rapamycin ameliorates experimental autoimmune myocarditis. Int Heart J 2005;46:513-530.
64. Ding L, Hanawa H, Ota Y, et al. Lipocalin-2/neutrophil gelatinase-B associated lipocalin is strongly induced in hearts of rats with autoimmune myocarditis and in human myocarditis. Circ J 2010;74:523-30.
65. Zhang S, Kodama M, Hanawa H, Izumi T, Shibata A, Masani F. Effects of cyclosporine, prednisolone and aspirin on rat autoimmune giant cell myocarditis. J Am Coll Cardiol 1993;21:1254-1260.
66. Hanawa H, Kodama M, Zhang S, Izumi T, Shibata A. An immunosuppressant compound, FK-506, prevents the progression of autoimmune myocarditis in rats. Clin Immunol Immunopathol 1992;62:321-326.
67. Kodama M, Hanawa H, Zhang S, et al. FK506 therapy of experimental autoimmune myocarditis after onset of the disease. Am Heart J 1993;126:1385-1392.
68. Hanawa H, Inomata T, Sekikawa H, Abo T, Kodama M, Izumi T, Shibata A. Analysis of heart-infiltrating T-cell clonotypes in experimental autoimmune myocarditis in rats. Circ Res 1996;78:118-125.
69. Yoshida T, Hanawa H, Toba K, et al. Expression of immunological molecules by cardiomyocytes and inflammatory and interstitial cells in rat autoimmune myocarditis. Cardiovasc Res 2005;68:278-288.
70. Matsumoto Y, Park IK, Kohyama K. Matrix metalloproteinase (MMP)-9, but not MMP-2, is involved in the development and progression of C protein-induced myocarditis and subsequent dilated cardiomyopathy. J Immunol 2009;183:4773-4781.
71. Hishikari K, Watanabe R, Ogawa M, et al. Early treatment with clarithromycin attenuates rat autoimmune myocarditis via inhibition of matrix metalloproteinase activity. Heart 2010;96:523-527.
72. Suzuki J, Isobe M, Aikawa M, et al. Nonmuscle and smooth muscle myosin heavy chain expression in rejected cardiac allografts. A study in rat and monkey models. Circulation 1996;94:1118-1124.
73. Suzuki J, Isobe M, Morishita R, et al. Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide. Nat Med 1997;3:900-903.
74. Suzuki J, Isobe M, Morishita R, Nishikawa T, Amano J, Kaneda Y. Prevention of cardiac allograft arteriosclerosis using antisense proliferating-cell nuclear antigen oligonucletide. Transplantation 2000;70:398-400.
75. Suzuki J, Isobe M, Morishita R, Nishikawa T, Amano J, Kaneda Y. Antisense bcl-x oligonucleotide induces apoptosis and prevents arterial neointimal formation in murine cardiac allografts. Cardiovasc Res 2000; 45:783-787.
76. Suzuki J, Morishita R, Amano J, Kaneda Y, Isobe M. Decoy against nuclear factor-kappa B attenuates myocardial cell infiltration and arterial neointimal formation in murine cardiac allografts. Gene Ther 2000;7:1847-1852.
77. Suzuki J, Cole S, Batirel S, et al. Tumor necrosis factor receptor-1 and -2 double deficiency reduces graft arterial disease in murine cardiac allografts. Am J Transplant 2003;3:968-976.
78. Suzuki J, Koga N, Kosuge H, Haraguchi G, Maejima Y, Saiki H, Isobe M. Pitavastatin suppresses acute and chronic rejection in murine cardiac allografts. Transplantation 2007;83:1093-1097.
79. Suzuki J, Ogawa M, Sagesaka YM, Isobe M. Tea catechins attenuate ventricular remodeling and graft arterial diseases in murine cardiac allografts. Cardiovasc Res 2006;69:272-279.
80. Suzuki J, Isobe M, Morishita R, Nagai R. Characteristics of chronic rejection in heart transplantation-Important elements of pathogenesis and future treatments. Circ J 2010;74:233-239.
81. Ogawa M, Suzuki J, Hishikari K, Takayama K, Tanaka H, Isobe M. Clarithromycin attenuates acute and chronic rejection via MMP suppression in murine cardiac transplantation. J Am Coll Cardiol 2008;51:1977-1985.
82. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990;81:1161-1172.
83. Yamamoto T, Eckes B, Mauch C, Hartmann K, Krieg T. Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1 alpha loop. J Immunol 2000;164:6174-6179.
84. Lalu MM, Csonka C, Giricz Z, Csont T, Schulz R, Ferdinandy P. Preconditioning decreases ischemia/reperfusion-induced release and activation of matrix metalloproteinase-2. Biochem Biophys Res Commun 2002;296:937-41.
85. Gallagher GL, Jackson CJ, Hunyor SN. Myocardial extracellular matrix remodeling in ischemic heart failure. Front Biosci 2007;12:1410-1419.
86. Giricz Z, Lalu MM, Csonka C, Bencsik P, Schulz R, Ferdinandy P. Hyperlipidemia attenuates the infarct size-limiting effect of ischemic preconditioning: Role of matrix metalloproteinase-2 inhibition. J Pharmacol Exp Ther 2006;316:154-161.
87. Nakajima T, Hishikari K, Ogawa M, et al. Clarithromycin attenuates myocardial ischemia reperfusion injury. Expert Opin Ther Targets 2010;14:881-893.
88. Blauwet LA, Cooper LT. Antimicrobial agents for myocarditis: Target the pathway, not the pathogen. Heart 2010;96:494-495.
89. De Francesco V, Giorgio F, Hassan C, et al. Worldwide H. pylori antibiotic resistance: A systematic review. J Gastrointestin Liver Dis 2010;19:409-414.
90. Kasahara K, Kita E, Maeda K, et al. Macrolide resistance of Streptococcus pneumoniae isolated during long-term macrolide therapy: Difference between erythromycin and clarithromycin. J Infect Chemother 2005;11:112-114.